In the Boardroom
Refine Search
Biotechnology
UK-based Qureight, a tech-bio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, has announced the appointment of Rebecca Simmons as chief operating officer (COO). 13 January 2026
Biotechnology
US biotech ecosystem company Alloy Therapeutics has appointed Christian Cobaugh as chief executive of its Genetic Medicines unit. 9 January 2026
Biotechnology
US commercial stage precision-care company Octave Bioscience has announced the appointment of Kirk Stockwood as senior vice president, commercial. Mr Stockwood will spearhead Octave’s commercial strategy as the company scales operations and expands the reach of its precision neurology platform. 9 January 2026
Biotechnology
Singapore headquartered biotech Nuevocor today announced the appointment of Al Gianchetti as chief executive (CEO) and member of the board of directors. 8 January 2026
Pharmaceutical
AstraZeneca’s new head of Investor Relations, Joris Silon, succeeds Andy Barnett on 1 March 2026, and will be based in Cambridge, UK. 8 January 2026
Biotechnology
Israeli-US biotech Biolojic Design has named experienced oncologist Roger Waltzman as chief medical officer, strengthening its leadership as it pushes forward a growing pipeline of artificial intelligence-designed antibody medicines in oncology and immunology. 8 January 2026
Pharmaceutical
UK biotech AstronauTx has appointed Adam Rosenberg as chairman of its board, succeeding Tim Edwards, as the company advances its sleep architecture-focused approach to treating Alzheimer’s disease and other neurological disorders. The appointment comes as AstronauTx prepares to move its programs toward early clinical development. 7 January 2026
Biotechnology
New York-based clinical-stage biotech LB Pharmaceuticals had announced the appointments of Ellen Rose as senior vice president, corporate affairs and Lindsay Beaupre as SVP people and culture. 7 January 2026
Biotechnology
Syncromune, a privately-held US biopharma developing SYNC-T, an in-situ platform combination immunotherapy optimized for solid tumor cancers, has announced the appointment of Stephen Dale as chief medical officer (CMO). 6 January 2026
Biotechnology
Dutch immunology company argenx announced that Karen Massey, current chief operating officer, will transition to chief executive (CEO) and executive director, and Tim Van Hauwermeiren, current chief executive, will transition to non-executive director and chairman. 6 January 2026
Biotechnology
Chris Murphy has been appointed chief executive of privately-held US genetic medicines company, ElevateBio, also joining its board of directors. 5 January 2026
Generics
Paul Burden has been appointed associate vice president and country head of Accord UK, effective immediately. 5 January 2026
Pharmaceutical
Abingworth, a transatlantic life sciences investment firm and part of global investment firm Carlyle, today announced several leadership changes. 5 January 2026
Biotechnology
German drug discovery company Evotec has announced the appointment of Dr Sarah Fakih as executive vice president, head of global communications and investor relations. 2 January 2026
Biotechnology
Charlie Gayer will become BioCryst's new chief executive effective January 1. 30 December 2025
Biotechnology
USA and Europe listed biotech PureTech has appointed Robert Lyne as chief executive (CEO), and as a member of the board of directors, effective immediately. 18 December 2025
Biotechnology
Switzerland-based Topadur Pharma, a biotech company developing innovative therapies for vascular regeneration, has announced the appointment of Matthias Schäfer as chief executive. 17 December 2025
Pharmaceutical
US clinical-stage oncology company NanOlogy has appointed David Arthur as chief executive, as it accelerates development of its large surface area microparticle drug platform and prepares a regulatory filing for a rare pediatric brain cancer program. 17 December 2025
Pharmaceutical
UK based liquid medicines maker Rosemont Pharmaceuticals has appointed an American chief executive (CEO) as the business continues to expand into the USA, Canadian and European pharma market. 16 December 2025
Biotechnology
Swedish rare disease specialist Hansa Biopharma announced a reorganization of its European and International Commercial and Medical Affairs operations. 15 December 2025
Biotechnology
US clinical-stage biotech Keros Therapeutics has announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065. 8 August 2025
Biotechnology
Biologics-focused contract manufacturing and research organization Abenza announced that Geoffrey Glass has been appointed chief executive (CEO), effective immediately. Mr Glass has served as chairman of the board since 2022. 6 August 2025
Biotechnology
Privately-held US clinical-stage biotech Cellergy Pharma announced the appointment Christopher Cano as chief executive (CEO). 5 August 2025
Pharmaceutical
Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective August 7, 2025. Mr Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective August 7. 4 August 2025
Biotechnology
ReAlta Life Sciences, a US biopharma seeking to address life-threatening rare and acute inflammatory diseases by rebalancing the inflammatory response, has announced the appointment of Ellen Lubman as chief business officer (CBO). 29 July 2025
Pharmaceutical
US pharma major Bristol Myers Squibb revealed it has appointed Dr Cristian Massacesi as executive vice president, chief medical officer and head of development, effective August 1, 2025. 26 July 2025
Pharmaceutical
UK-based Rosemont Pharmaceuticals has appointed a new chair with a wealth of experience in the US pharma market. 23 July 2025
Biotechnology
UK government-backed Cell and Gene Therapy Catapult (CGT Catapult), a tech and innovation organization specializing in the advancement of the cell and gene therapy industry, has appointed Ed Samuel as its chief operations officer (COO). 23 July 2025
Pharmaceutical
French pharma Ipsen (Euronext: IPN) today announced the following changes to its executive committee: 23 July 2025
Biotechnology
After 13 years at the helm of the UK’s BioIndustry Association, Steve Bates has tendered his resignation as chief executive of the BIA to take up a newly created position announced today as executive chair for the Office of Life Science within the UK government. His last day at the BIA will be Friday, September 26, 2025. 23 July 2025
Pharmaceutical
Neuraxpharm Group, a privately-held German specialty pharma focused on central nervous system (CNS) disorders, today announced the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed head of commercial, Avendran Naidu, as the company continues to expand globally. 22 July 2025
Pharmaceutical
The Association of the British Pharmaceutical Industry (ABPI) has appointed Laura McMullin as vice president of the trade group. 22 July 2025
Biotechnology
NodThera, a privately-held biotech working in chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, has announced the appointment of Jyothis George as chief medical officer (CMO), effective immediately. 21 July 2025
Biotechnology
German mRNA specialist BioNTech has announced that Ryan Richardson will step down from his position as chief strategy officer and member of the management board. 18 July 2025
Biotechnology
US biotech TRIO Pharmaceuticals has announced the appointment of Patrick Doyle as chief executive (CEO effective immediately. 18 July 2025
Biotechnology
Scottish biotech Trogenix has announced two senior appointments as the company advances its pipeline towards the clinic. 18 July 2025
Pharmaceutical
Bayer is giving chief executive Bill Anderson more time to deliver on his ambitious efforts to reshape the German group, extending his contract by three years to March 2029. The move signals strong support from the company’s supervisory board, which voted unanimously in favor of the renewal. 17 July 2025
Biotechnology
Bharatt Chowrira has stepped down from his role as chief executive (CEO) and board member at US biopharma PureTech Health. 16 July 2025
Biotechnology
US biotech Tract Bio has appointed Chris Galloway as chief medical and development officer, as it prepares for an investigational new drug filing for its lead oncology candidate, TP-101, within the next 18 months. The Boston-based company is also expanding its board with two senior figures from the oncology and biotech world: Mark Adler and Kristiina Vuori. 15 July 2025
Biotechnology
Swiss clinical-stage CNS disease specialist Synendos Therapeutics has named Dr George Garibaldi as its chief medical officer (CMO). 15 July 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze